1. Home
  2. MAC vs RYTM Comparison

MAC vs RYTM Comparison

Compare MAC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macerich Company (The)

MAC

Macerich Company (The)

SELL

Current Price

$24.06

Market Cap

7.0B

Sector

Real Estate

ML Signal

SELL

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

SELL

Current Price

$116.57

Market Cap

6.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MAC
RYTM
Founded
1964
2008
Country
United States
United States
Employees
2845
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.3B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
MAC
RYTM
Price
$24.06
$116.57
Analyst Decision
Buy
Strong Buy
Analyst Count
16
19
Target Price
$26.87
★ $140.12
AVG Volume (30 Days)
★ 2.7M
1.6M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
★ 2.73%
N/A
EPS Growth
11.36
★ 28.34
EPS
★ N/A
N/A
Revenue
★ $1,013,983,000.00
N/A
Revenue This Year
N/A
$74.20
Revenue Next Year
$8.59
$74.91
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 10.43
N/A
52 Week Low
$16.03
$74.50
52 Week High
$26.68
$122.20

Technical Indicators

Market Signals
Indicator
MAC
RYTM
Relative Strength Index (RSI) 46.97 62.72
Support Level $23.16 $82.31
Resistance Level $25.96 $119.75
Average True Range (ATR) 0.59 7.90
MACD -0.09 1.52
Stochastic Oscillator 9.00 94.01

Price Performance

Historical Comparison
MAC
RYTM

About MAC Macerich Company (The)

Macerich invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and nine regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $199 in sales per square foot over the 12 months ended in June 2026.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: